癌症研究
生物
肺癌
表皮生长因子受体
酪氨酸激酶
后天抵抗
吉非替尼
癌症
医学
肿瘤科
内科学
受体
作者
Yukie Kashima,Daisuke Shibahara,Ayako Suzuki,Kyoko Muto,Ikei S. Kobayashi,David Plotnick,Hibiki Udagawa,Hiroki Izumi,Yuji Shibata,Kosuke Tanaka,Masanori Fujii,Akihiro Ohashi,Masahide Seki,Kōichi Goto,Katsuya Tsuchihara,Yutaka Suzuki,Susumu Kobayashi
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-07-09
卷期号:81 (18): 4835-4848
被引量:102
标识
DOI:10.1158/0008-5472.can-20-2811
摘要
experiments demonstrated that CD74 upregulation confers resistance to the EGFR-TKI osimertinib and blocks apoptosis, enabling tumor regrowth. Overall, this study provides new insight into the mechanisms underlying resistance to EGFR-TKIs. SIGNIFICANCE: Single-cell analyses identify diverse mechanisms of resistance as well as the state of tolerant cells that give rise to resistance to EGFR tyrosine kinase inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI